Pfizer’s Covid Booster Shot for Younger Teens Wins FDA Clearance, Stock Drops (But Pfizer Underperformed S&P 500 Index Since Fed COVID Stimulus)

You would think that an FDA approval to give booster shots to millions of new patients would send their stock soaring. It didn’t Pfizer dropped along with the S&P 500 index.

Despite the growth of COVID cases in the US (blue dashed line), Pfizer stock has only gone up by “only” 88% since March 2020. The S&P 500 index rose by 100%.

I under what Pfizer’s performance would be if The Fed wasn’t blowing a hurricane wind at the back of the market.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.